Neurodegenerative disease: Establishing a clinical trial battery for Huntington disease

Nature Reviews Neurology

Volumn 8, Issue 5, 2012, Pages 250-251

  Paulsen, Jane S ^a   Long, Jeffrey D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN SIZE; BRAIN VENTRICLE; CAUDATE NUCLEUS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EFFECT SIZE; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUTAMEN; REVIEW; WHITE MATTER;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME;

EID: 84860889284     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.67     Document Type: Review

References (5)

1. Paulsen, J. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr. Neurol. Neurosci. Rep. 11, 474-483 (2011).
2. Ross, C. A. & Tabrizi, S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98 (2011).
3. Mazurová, Y., Guncová, I., Látr, I. & Rudolf, E. Intervention of proliferation and differentiation of endogenous neural stem cells in the neurodegenerative process of Huntington's disease phenotype. CNS Neurol. Disord. Drug Targets 10, 486-499 (2011).
4. Paulsen, J. S., Early detection of Huntington's disease. Future Neurol. 5, 85-104 (2010).
5. Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012).